New developments in the management of chronic lymphocytic leukemia: role of ofatumumab - Wikidata - wikimedia - TriplyDB

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

http://www.wikidata.org/entity/Q26768396

about

New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

P2860

Q47221234-50D4BF28-FCD4-4BF1-883E-E61053ACCF63

P2860

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

http://www.wikidata.org/entity/Q26768396

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@ast

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@en

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@nl

type

label

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@ast

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@en

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@nl

prefLabel

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@ast

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@en

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@nl

P1433

Q26768396-FEEE641D-B00A-4A6D-843D-E6CFA6537B72

P1476

Q26768396-781C8ABF-4CFE-440F-B5AE-5FEAA679220D

P2093

Q26768396-834DEAFA-3115-40FD-B986-2A38FEA92378

Q26768396-94D8B4C2-7A1E-4AC0-9BFF-4B8DD5F2789F

Q26768396-B3B85462-B6E8-4767-9D3A-537B777B01E5

Q26768396-D17662D0-202D-4D98-9436-7632A0FDDD13

P2860

Q26768396-139DA6B2-C9AC-45B6-BC7B-DD291CB12A92

Q26768396-1408FC20-A489-4481-B238-83AAADDD2388

Q26768396-169BCDDC-E60B-4EA4-BA0D-1EB49F24BDCD

Q26768396-18487725-1ED9-48C3-871D-4ECD8035F8F0

Q26768396-25E84449-31BE-4E16-A6CB-9F0463E314A9

Q26768396-297E4740-4230-4F4C-B936-45B1B8370E48

Q26768396-2EC11502-B9AB-422A-A030-EFD9F50F1335

Q26768396-37FFB5B5-D102-4F8F-9ED4-B51F737CCB84

Q26768396-409633EC-DBD7-4CE9-82C3-21A55F204125

Q26768396-54C4383F-0489-47F8-A953-67C0BB4AC76B

P304

Q26768396-693F4AE5-1445-435E-904B-EB44928C24EE

P31

Q26768396-18D51AC8-6D22-4B6F-890B-E53695D482F0

P356

Q26768396-1BE64521-73FB-4874-B40B-49B046C09D66

P407

Q26768396-6BE4C71A-28B9-441D-ABE8-19E746D154AD

P478

Q26768396-B8F5D909-ED18-47BE-B14C-2C42FA252451

P50

Q26768396-13EC63D4-F256-4317-B97F-8DCAE358D829

P577

Q26768396-B77D5D29-80DC-442E-A4CC-934DD3610E14

P698

Q26768396-0267635A-D3C4-4962-9490-9E2FFFE836BB

P921

Q26768396-77B90FB8-F19A-481E-9BEB-515957BD5877

Q26768396-F7C80BF3-8AC2-4AEC-B7D4-C9093C66A960

P932

Q26768396-934DC594-CFE9-46E7-9C2B-22008039EDDE

P356

P1433

OncoTargets and Therapy

P1476

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

@en

P2093

Francesco Autore

http://www.w3.org/2001/XMLSchema#string

Idanna Innocenti

http://www.w3.org/2001/XMLSchema#string

Luca Laurenti

http://www.w3.org/2001/XMLSchema#string

Simona Sica

http://www.w3.org/2001/XMLSchema#string

P2860

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

P304

421-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S72845

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Dimitar Efremov

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26855591

http://www.w3.org/2001/XMLSchema#string

P921

P932

4725726

http://www.w3.org/2001/XMLSchema#string